[S-8] Ultragenyx Pharmaceutical Inc. Employee Benefit Plan Registration

Filing Impact

(No impact)

Filing Sentiment

(Neutral)

Form Type

S-8

Rhea-AI Filing Summary

Analyzing...

07/18/2025 - 04:02 PM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Ultragenyx Pharm

NASDAQ:RARE

RARE Rankings

#2152 Ranked by Market Cap

N/A Ranked by Dividends

RARE Latest News

Jul 18, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Jul 9, 2025

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Jun 27, 2025

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Jun 20, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE Latest SEC Filings

Jul 11, 2025

[8-K] Ultragenyx Pharmaceutical Inc. Reports Material Event

Jul 9, 2025

[8-K] Ultragenyx Pharmaceutical Inc. Reports Material Event

Jun 27, 2025

[8-K] Ultragenyx Pharmaceutical Inc. Reports Material Event

Jun 23, 2025

[Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading Activity

Jun 20, 2025

[144] Ultragenyx Pharmaceutical Inc. SEC Filing

RARE Stock Data

Market Cap 2.93B

Float 90.51M

Insiders Ownership 3.65%

Institutions Ownership 98.31%

Short Percent 4.96%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City NOVATO